What Sivan Innovation does

Sivan Innovation is an Israel-based medical technology company founded in 2014 that develops Moovcare, a regulated medical telesurveillance platform for adult cancer patients. The product operates through a web-based application on which patients complete weekly structured questionnaires via smartphone, tablet, or computer to report health status and symptoms. The submitted data is analyzed by a clinical algorithm and then reviewed by a dedicated in-house team of oncology-specialized physicians and nurses; when concerning signals are detected, the team contacts the patient and informs the treating oncologist to enable rapid intervention. The company holds Class IIa medical device status with CE marking under EU MDR in Europe and Class I medical device designation in Canada, positioning Moovcare as a prescription telesurveillance device rather than a wellness app.

Sivan offers three specialized product modules on top of the core platform: Moovcare (general cancer telemonitoring), Moovcare Poumon (lung cancer-specific monitoring), and Moovcare Toxicite (early detection of treatment-related toxicities), supplemented by a Soins de Support (supportive care) module that captures patient-reported well-being and returns personalized advice. The technology stack is essentially a structured patient-reported outcomes (PRO) capture system combined with algorithmic signal detection and human clinical review, with the company explicitly stating it does not interfere with the oncologist's therapeutic decisions. Clinical validation is the central evidence asset: studies on more than 3,000 patients have been published in peer-reviewed journals including the Journal of Thoracic, JNCI, JAMA, and ASCO, and a 2026 Institut Curie study reported that 94% of patients found the application easy to use. The company is privately held, with headquarters in Ra'anana, Israel, a French subsidiary (Sivan France) in Asnieres-sur-Seine, and EU Authorized Representation via Kapsicum in Saclay, France.

Sivan operates a subscription-based revenue model, selling Moovcare as a recurring telesurveillance medical device reimbursed in France under the national telesurveillance framework. The go-to-market motion is sales-led and focused on oncology teams and cancer treatment centers, with direct patient enrollment supported through the Moovcare website. The customer base spans 'thousands of patients' cumulatively across Israel, France, and Canada. Leadership comprises CEO Ayala Bliah and President/Founder Daniel Israel. The company has no public funding rounds, ownership disclosures, or revenue figures, and operates with 11-50 employees, indicating a small, founder-driven organization that has prioritized clinical evidence and regulatory certification over rapid headcount or capital scaling.

Name

Sivan Innovation

Legal name

Sivan Innovation

Website

https://sivan-innovation.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

Sivan Innovation is an Israel-based medical technology company that develops Moovcare, a CE-marked Class IIa telesurveillance medical device for adult cancer patients, combining weekly patient-reported questionnaires with algorithm-driven analysis and oncology-supervised monitoring across Israel, France, and Canada.

Ownership category

akta.pro rank

Product category

Oncology Remote Patient Monitoring (Medical Device Software)

NAICS

Computer Systems Design and Related Services (54151)

SIC

Surgical & Medical Instruments & Apparatus (3841), Services-Misc Health & Allied Services, Nec (8090)

akta.pro primary industry

Oncology Remote Symptom Monitoring & Care Navigation (HLALAFAD)

akta.pro secondary industries

Oncology Telemedicine Platforms (HLALAGAH), Thoracic (Lung) Oncology (HLAKAFAL)

Keywords

• Cancer telesurveillance
• Oncology remote monitoring
• Medical device software
• Patient symptom tracking
• Digital health oncology

Headquarters

HQ city

Jerusalem

HQ country

Israel

HQ region

Middle East

Offices3 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Medical Device Subscription: Moovcare operates as a regulated medical device (Class IIa in Europe, Class I in Canada) sold through a subscription model to cancer patients under oncology team supervision. The solution is reimbursed as a telesurveillance medical device in France and operates in coordination with healthcare providers.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

Sivan Innovation develops and sells Moovcare, a regulated medical telesurveillance device (Class IIa CE-marked in Europe, Class I in Canada) that monitors cancer patients between oncology consultations via weekly web-based questionnaires analyzed by a clinical algorithm and supervised by an oncology-specialist medical team. Specialized variants target lung cancer (Moovcare Poumon) and treatment-related toxicities (Moovcare Toxicité), with a Soins de Support module for supportive care.

Product overview

Sivan Innovation offers Moovcare, a suite of medical telemonitoring products designed for cancer patients. The core offering consists of Moovcare (general cancer telemonitoring) and two specialized solutions: Moovcare® Poumon for lung cancer patients and Moovcare® Toxicité for detecting treatment-related toxicities. All products operate through weekly patient questionnaires analyzed by algorithms and supervised by oncology medical teams, with the Soins de Support module providing additional supportive care recommendations. The solutions are Class IIa medical devices with CE marking (Europe) and Class I designation (Canada).

Differentiator

Problem solved

Functional benefit

Brands

• Moovcare: Medical telemonitoring device for cancer patients, including Moovcare® Poumon (lung cancer telemonitoring) and Moovcare® Toxicité (treatment toxicity detection). Class IIa medical device with CE marking for Europe, Class I for Canada.

Products and services

• Moovcare Class IIa CE-marked medical telesurveillance device for adult cancer patients under oncology team supervision. Enables weekly web-based symptom questionnaires analyzed by a clinical algorithm and supervised by an oncology-specialist medical team, which alerts the patient's oncologist when clinical signals require attention.
• Moovcare Poumon Web-application for personalized telemonitoring of patients with lung cancer, enabling early detection of relapses and complications related to lung cancer through weekly questionnaires reviewed by oncology specialists.
• Moovcare Toxicité Web-application dedicated to early detection of toxicities related to anticancer treatments, leveraging the Moovcare weekly questionnaire and oncology-supervised analysis workflow to flag treatment side effects for rapid intervention.

Quantifiable outcome

• 94% of patients find the application easy to use (clinical study, Institut Curie 2026)
• +2 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• Institut CuriecoreStrategic or Co-development Partner · 1 January 2026Institut Curie conducted clinical research on Moovcare, including a study demonstrating that 94% of patients find the application easy to use. The partnership provides clinical validation and peer-reviewed evidence for the Moovcare solution.
• KapsicumcoreImplementation/ SI/ Consulting PartnerKapsicum serves as the EU Authorized Representative for Sivan Innovation, located at 4 rue René Razel, 91400 Saclay, France. As EU REP, Kapsicum ensures regulatory compliance for medical devices distributed in the European market.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• Huma Therapeutics: Huma is a regulated digital health platform offering remote patient monitoring across multiple therapeutic areas including oncology, representing an adjacent emerging player with broader scope but overlapping technology and regulatory positioning.
• Kaia Health: Kaia Health is a digital therapeutics company delivering regulated software medical devices via subscription, sharing Moovcare's model of selling app-based, clinically validated digital therapies to patients under medical supervision.
• Caresense Health: Caresense Health focuses on remote patient monitoring for oncology, addressing a similar use case to Moovcare for tracking symptoms and outcomes between visits, with comparable clinical evidence-driven positioning.

Broad incumbents

• Varian (Siemens Healthineers): Varian, now part of Siemens Healthineers, provides oncology treatment software and increasingly patient-facing digital tools, positioning it as a broad incumbent capable of embedding symptom monitoring into its oncology care platform.
• Flatiron Health: Flatiron Health (Roche) provides oncology-specific electronic health records, analytics, and real-world data, and represents a broad incumbent that can extend into patient monitoring and evidence generation for oncology care pathways.
• Elekta: Elekta is a major oncology technology vendor (radiotherapy, software) that acquired Noona to extend into patient engagement. It represents the broader incumbent ecosystem Sivan competes against for oncology IT budgets and clinical workflow integration.

Direct peers

• Navigating Cancer: Navigating Cancer offers a patient-facing platform for cancer symptom tracking, education, and care team communication, addressing the same use case of continuous monitoring between oncology consultations that Moovcare serves.
• Noona Healthcare (Elekta): Noona is an oncology patient engagement and symptom-tracking platform acquired by Elekta, offering direct overlap with Moovcare's cancer telemonitoring value proposition. It targets the same oncology teams and patient populations with a comparable PRO-based monitoring workflow.
• Carevive Systems: Carevive provides oncology-specific remote symptom monitoring and care management software to cancer centers, closely mirroring Moovcare's model of capturing patient-reported outcomes and triggering clinician intervention for cancer patients.
• Voluntis (Aptar Digital Health): Voluntis develops regulated digital therapeutic software (SaMD) for chronic conditions, sharing Moovcare's positioning as a CE-marked, prescription-based software medical device with similar reimbursement-driven commercial dynamics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/sivaninnovatio5
• YouTubeyoutube.com/channel/UC4fOM7l4Rg3LfCdUEr-2iHA
• LinkedInlinkedin.com/company/sivan-innovation

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sivan Innovation